Sacubitril/valsartan reduces serum uric acid concentration, in PARADIGM-HF
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PARADIGM-HF
- 28 Aug 2023 Results presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 16 Jun 2022 Results assessing prescription rate of conventional medical therapy and its association with long-term outcomes using enrollment criteria from PARADIGM-HF/DAPA-HF and SHIFT trials published in the International Journal of Cardiology
- 03 Dec 2021 Data was used from this trial to develop a Markov model assessing projected Health Outcomes with Real-World Versus Optimal Usage of Sacubitril/Valsartan in Portugal presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research